433 related articles for article (PubMed ID: 7511039)
1. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy.
Pollack A; Zagars GK; el-Naggar AK; Gauwitz MD; Terry NH
Cancer; 1994 Apr; 73(7):1895-903. PubMed ID: 7511039
[TBL] [Abstract][Full Text] [Related]
2. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
Pollack A; Zagars GK; el-Naggar AK; Terry NH
Urology; 1994 Nov; 44(5):711-8. PubMed ID: 7526527
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy.
Gauwitz MD; Pollack A; el-Naggar AK; Terry NH; von Eschenbach AC; Zagars GK
Int J Radiat Oncol Biol Phys; 1994 Mar; 28(4):821-8. PubMed ID: 8138434
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study.
Lanza G; Gafà R; Santini A; Maestri I; Dubini A; Gilli G; Cavazzini L
Cancer; 1998 Jan; 82(1):49-59. PubMed ID: 9428479
[TBL] [Abstract][Full Text] [Related]
5. DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure.
Borre M; Høyer M; Nerstrøm B; Overgaard J
Prostate; 1998 Sep; 36(4):244-9. PubMed ID: 9719024
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
7. The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation.
Pollack A; Troncoso P; Zagars GK; von Eschenbach AC; Mak AC; Wu CS; Terry NH
Prostate; 1997 Apr; 31(1):21-8. PubMed ID: 9108882
[TBL] [Abstract][Full Text] [Related]
8. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy.
Khoo VS; Pollack A; Cowen D; Joon DL; Patel N; Terry NH; Zagars GK; von Eschenbach AC; Meistrich ML; Troncoso P
Prostate; 1999 Nov; 41(3):166-72. PubMed ID: 10517874
[TBL] [Abstract][Full Text] [Related]
9. DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer.
Badalament RA; O'Toole RV; Young DC; Drago JR
Cancer; 1991 Jun; 67(12):3014-23. PubMed ID: 1710533
[TBL] [Abstract][Full Text] [Related]
10. Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis.
Nativ O; Winkler HZ; Raz Y; Therneau TM; Farrow GM; Myers RP; Zincke H; Lieber MM
Mayo Clin Proc; 1989 Aug; 64(8):911-9. PubMed ID: 2796401
[TBL] [Abstract][Full Text] [Related]
11. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors.
Zincke H; Bergstralh EJ; Larson-Keller JJ; Farrow GM; Myers RP; Lieber MM; Barrett DM; Rife CC; Gonchoroff NJ
Cancer; 1992 Jul; 70(1 Suppl):311-23. PubMed ID: 1600493
[TBL] [Abstract][Full Text] [Related]
12. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H
J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
14. Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy.
Hawkins CA; Bergstralh EJ; Lieber MM; Zincke H
Urology; 1995 Sep; 46(3):356-64. PubMed ID: 7544934
[TBL] [Abstract][Full Text] [Related]
15. DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy.
Keyes M; Macaulay C; Hayes M; Korbelik J; Morris WJ; Palcic B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):829-34. PubMed ID: 23688814
[TBL] [Abstract][Full Text] [Related]
16. Value of nuclear DNA ploidy patterns in patients with prostate cancer after radical prostatectomy.
Wirth MP; Müller HA; Manseck A; Müller J; Frohmüller HG
Eur Urol; 1991; 20(3):248-52. PubMed ID: 1823048
[TBL] [Abstract][Full Text] [Related]
17. In treating localized prostate cancer the efficacy of cryoablation is independent of DNA ploidy type.
Bahn DK; Silverman P; Lee F; Badalament R; Bahn ED; Rewcastle JC
Technol Cancer Res Treat; 2004 Jun; 3(3):253-7. PubMed ID: 15161318
[TBL] [Abstract][Full Text] [Related]
18. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis.
Montgomery BT; Nativ O; Blute ML; Farrow GM; Myers RP; Zincke H; Therneau TM; Lieber MM
Arch Surg; 1990 Mar; 125(3):327-31. PubMed ID: 2306181
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Zagars GK; Pollack A
Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
Lankford SP; Pollack A; Zagars GK
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
